<DOC>
	<DOCNO>NCT01262846</DOCNO>
	<brief_summary>The overall goal study compare safety immunogenicity trivalent Fluzone® High-Dose vaccine v regular standard-dose ( SD ) HIV infected individual . Our hypothesis Fluzone® HD safe immunogenic currently use vaccine</brief_summary>
	<brief_title>Improving Immunogenicity Influenza Vaccine HIV Infected Individuals</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . A confirmed diagnosis HIV1 infection document licensed ELISA test kit confirm Western blot time prior study entry measurable HIV RNA viral load chart . Serum HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . &gt; 18 year 3 . Able understand comply plan study procedure . 4 . Provides write informed consent prior initiation study procedure . 5 . Subject 1 ) stable antiretroviral therapy outline DHHS treatment guideline HIV1 infected individual OR 2 ) antiretroviral therapy intend start treatment within next 30 day . 1 . Has know allergy egg component vaccine ( may include , limited : gelatin , formaldehyde , octoxinol chicken protein ) . 2 . Has history , opinion site investigator , severe reaction follow previous immunization seasonal TIV . 3 . Participation novel H1N1 influenza vaccine study past two year . 4 . Proven history , RTPCR , novel influenza H1N1 infection , , positive influenza diagnostic testing since June 2009 ( specificity H1N1 require ) prior study entry . 5 . Received live license vaccine within 4 week inactivate licensed vaccine within 1 week prior study entry . 6 . Scheduled administration live virus vaccine inactivate vaccine entry Day 21 visit . NOTE : Live inactivate vaccine expect administer study entry Day 21 visit exclude prevent potential interference immunogenicity responses confound safety result . 7 . Received nonlicensed agent ( vaccine , drug , biologic , device , blood product , medication ) within 4 week prior vaccination study exception new antiretroviral medication part phase 3 trial . 8 . An acute illness and/or oral temperature great equal 100.0 degree F within 24 hour prior study entry . 9 . Use anticancer chemotherapy radiation therapy within precede 36 month study enrollment , immunosuppression result underlie illness treatment ( HIV1 infection ) . 10 . Active neoplastic disease ( exclude nonmelanoma skin cancer , HPVrelated cervical dysplasia , CIN grade 1 , 2 3 ) . 11 . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , HIV vaccine , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . NOTE : Subjects receive stable physiologic glucocorticoid dos , define prednisone ≤10 mg/day , exclude . Subjects receive corticosteroid acute therapy opportunistic infection Pneumocystis jiroveci pneumonia ( PCP ) , receive short course ( defined ≤2 week ) pharmacologic glucocorticoid therapy exclude . 12 . Received immunoglobulin blood product 13 . Current diagnosis uncontrolled major psychiatric disorder . 14 . History GuillainBarré Syndrome subject subject 's family ( parent , sibling , half sibling , child ) . 15 . Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Flu vaccination</keyword>
	<keyword>HIV infect individual</keyword>
	<keyword>Fluzone SD</keyword>
	<keyword>Fluzone HD</keyword>
</DOC>